GlassScriptPhysician profile
Lynne Clark
NPI 1598451361
$5,151.49
in general payments reported to CMS, 2019-2025
25 companies · $2,273 in 2025
The $2,273 reported for 2025 was more than what 97% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,035 · 2024: $1,843 · 2025: $2,273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,151.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,151.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $940.38 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $573.80 | 2023-2025 | |
| Gilead Sciences, INC. | $508.34 | 2024-2025 | Yeztugo, Epclusa, Descovy |
| Phathom Pharmaceuticals, INC. | $484.21 | 2024-2025 | Voquezna |
| Glaxosmithkline, LLC. | $419.40 | 2024-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Novo Nordisk INC | $366.17 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $277.86 | 2023-2024 | Invega Sustenna, Spravato |
| Lilly USA, LLC | $251.71 | 2023-2025 | Jardiance, Mounjaro, Zepbound |
| Exact Sciences Corporation | $216.09 | 2023-2025 | Cologuard Collection Kit |
| Abbvie INC. | $175.49 | 2023-2025 | |
| Insulet Corporation | $170.43 | 2024-2025 | Omnipod |
| Pfizer INC. | $162.85 | 2024-2025 | |
| Idorsia Pharmaceuticals US INC | $124.99 | 2023 | Quviviq |
| Abbott Laboratories | $94.97 | 2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $76.45 | 2024 | Veozah |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $62.28 | 2025 | Nuzyra, Xhance |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $48.15 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $35.59 | 2023-2024 | Camzyos, Eliquis |
| Boston Scientific Corporation | $32.08 | 2025 | Watchman Flx |
| Viiv Healthcare Company | $31.35 | 2025 | Apretude |
| Averitas Pharma INC. | $28.37 | 2025 | Qutenza |
| Dexcom, INC. | $21.05 | 2025 | Dexcom G6 Transmitter |
| Amgen INC. | $18.70 | 2024 | Otezla, Repatha |
| Esperion Therapeutics, INC. | $15.85 | 2025 | Nexletol |
| Seqirus USA INC | $14.93 | 2025 | Fluad, Flucelvax |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lynne Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.